Determination of Regulatory Review Period for Purposes of Patent Extension; VRAYLAR

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for VRAYLAR, a human drug product, following the submission of patent extension applications to the U.S. Patent and Trademark Office (USPTO). This determination is being published as required by law.